ILCN.org (ILCN/WCLC) ILCN.org (ILCN/WCLC)
twitter youtube facebook linkedin iaslc Home
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
Menu
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
loading...
Home Industry News & Regulatory Approvals

Pragmatic Approach to Trial Design Born from Lung-MAP Substudy

Erin Jungmeyer
on: March 21, 2023In: Evolving Standards of Care, Industry News & Regulatory Approvals
Pragmatic Approach to Trial Design Born from Lung-MAP Substudy

In a recent interview with ILCN, the US FDA’s Dr. Harpreet Singh discusses the confirmatory Pragmatica-Lung trial and how the agency’s new pragmatic approach to trial design can streamline research and ultimately benefit patients. Read more


Narrow Focus Allows Pragmatica-Lung Trial to Minimize Eligibility Criteria, Significantly Reduce Data Collection, Researcher Says

Erin Jungmeyer
on: March 07, 2023In: Evolving Standards of Care, Industry News & Regulatory Approvals, Uncategorized
Narrow Focus Allows Pragmatica-Lung Trial to Minimize Eligibility Criteria, Significantly Reduce Data Collection, Researcher Says

In a recent interview with ILCN, Dr. Karen Reckamp discussed the overall survival implications from the phase II Lung-MAP study and how the phase III follow-up Pragmatica-Lung trial aims to confirm that specific endpoint. Read more

In Brief for Feb. 8, 2023

John Austin
on: February 07, 2023In: Industry News & Regulatory Approvals, Names & News
In Brief for Feb. 8, 2023

Dr. Carolyn Dresler Joins Action on Smoking and Health (ASH) Board of Trustees; Novel Liquid Biopsy Assay for Lung Carcinoma Detection Receives FDA Breakthrough Device Designation. Read more

In Brief for January 25, 2023

John Austin
on: January 24, 2023In: Industry News & Regulatory Approvals, Society News
In Brief for January 25, 2023

China approves mobocertinib for patients with EGFR Exon20 insertion+ NSCLC; Deadline approaching for IASLC 2023 Lectureship and Distinguished Service Award Nominations. Read more

In Brief for Jan. 11, 2023

John Austin
on: January 10, 2023In: Industry News & Regulatory Approvals
In Brief for Jan. 11, 2023

Japan greenlights durvalumab and tremelimumab in combination with chemotherapy; US approves companion diagnostic tool for certain TKIs and expands indications for pemetrexed injection. Read more

Regulatory News for Nov. 23, 2022

Erin Jungmeyer
on: November 22, 2022In: Industry News & Regulatory Approvals
Regulatory News for Nov. 23, 2022

US Food and Drug Administration approves two combinations for non-small cell lung cancer. Read more

Real-World Data from Taiwan Shows Stage Shift Has Improved Lung Cancer Survival Rates

Pan-Chyr Yang, MD, PhD
+more
on: June 07, 2022In: Evolving Standards of Care, Industry News & Regulatory Approvals
Real-World Data from Taiwan Shows Stage Shift Has Improved Lung Cancer Survival Rates

Researchers say increased screening of at-risk populations, including those who have never smoked, may improve survival more than any other strategy. Read more

US FDA’s Review of Single-Country ‘Me Too’ Drugs: A Clinical Trialist Perspective

Matthew Z. Guo, BA
+more
on: May 24, 2022In: Industry News & Regulatory Approvals
US FDA’s Review of Single-Country ‘Me Too’ Drugs: A Clinical Trialist Perspective

With no direct comparison to the standard of care and limited resources to review applications, researchers say they support the agency’s decision not to approve sintilimab. Read more

In Brief for May 25, 2022

Erin Jungmeyer
on: May 24, 2022In: Industry News & Regulatory Approvals, Meeting News, Names & News, Society News
In Brief for May 25, 2022

5th edition of patient education book released; US FDA moves to prohibit tobacco flavoring. Read more

In Brief for May 11, 2022

Erin Jungmeyer
on: May 11, 2022In: Industry News & Regulatory Approvals, Names & News
In Brief for May 11, 2022

Winship Cancer Institute announces preceptor opportunity. NICE recommends tepotinib for select patients. Read more

12345
IASLC Logo
ILCN Editorial Group    IASLC.org   

Advertise with Us   

© 2023 IASLC. All Rights Reserved. Powered By TriStar Event Media, LLC   Privacy Policy